G
Glooko
Unified platform for diabetes management
About Glooko
Glooko provides a unified platform for diabetes management, connecting patients, providers, and devices to simplify diabetes care. The platform syncs data from various diabetes devices, including blood glucose meters, insulin pumps, and smart pens, to provide actionable insights for better treatment decisions. The company serves both people with diabetes and healthcare providers, including endocrinologists, nurses, diabetes educators, and primary care providers.
Read full description
Glooko's platform aims to streamline workflows for healthcare professionals and deliver measurable health outcomes for patients. By unifying data from a variety of devices, Glooko makes diabetes management easier and more efficient. The company operates in the digital health and diabetes care market, offering a data management solution that enhances the connection between patients and their care teams.
At a glance
- Status
- Operational
- Founded
- 2010
- Headquarters
- Palo Alto, United States
- Employees
- 237
- Open positions
- None listed
- Dealroom signal
- 68.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Health Platform
- Sector
- Biotech & Life Sciences, Personal Health, Diabetes, Testing, Risk Management, Data Analytics, Biotechnology, Remote Monitoring, Metabolism, Digital Therapeutics
- Client focus
- b2b, b2c
- Investment activity
- 4 companies, latest Sep 2025
- Capital deployed
- —
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES FOther financing | Oct 2024 | $100M | $400M | Health Catalyst Capital · Georgian · Canaan | ↗ |
| SERIES DOther financing | Mar 2021 | $30M | $175M | Canaan · Health Catalyst Capital · Novo Nordisk · Mayo Clinic | — |
Growth signals
Latest recorded traffic for Glooko is 210K monthly website visits, up 40% over the last three months. Glooko's team declined 13.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Monarch Medical TechnologiesIdaho Falls, United StatesA digital health company committed to helping hospitals and health systems deliver optimal glycemic management for critical care and non-critical care patients alike
→
DIABNEXTTaiwanSet of connected devices and software that collect and analyze the main metrics of diabetes
→
xbirdBerlin, GermanyAI based personalization of diabetes therapy
→
DiasendGöteborgs Stad, SwedenDiasend® makes management of your diabetes data simple. One solution, no fuss. FREE for home users! diasend® is built on your feedback, so make yourself heard!
→
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A5 investors entered at this stage
Samsung Ventures- LVLifeforce Ventures
Samsung Next
Canaan
Medtronic
Series B and later5 investors entered at this stage
Georgian
Health Catalyst Capital
Novo Nordisk
Mayo Clinic
Insulet
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Glooko on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Glooko’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.